US6288237B1
(en)
|
1995-11-17 |
2001-09-11 |
Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) |
Epothilons C and D, preparation and compositions
|
CN1196698C
(zh)
|
1996-11-18 |
2005-04-13 |
生物技术研究有限公司(Gbf) |
Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
|
US6867305B2
(en)
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
JP4579351B2
(ja)
|
1996-12-03 |
2010-11-10 |
スローン−ケッタリング インスティトュート フォア キャンサー リサーチ |
エポチロンの合成とその中間体及びその類似物並びにその使用
|
US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6660758B1
(en)
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
US6380394B1
(en)
|
1996-12-13 |
2002-04-30 |
The Scripps Research Institute |
Epothilone analogs
|
US6441186B1
(en)
|
1996-12-13 |
2002-08-27 |
The Scripps Research Institute |
Epothilone analogs
|
HU228851B1
(en)
*
|
1997-02-25 |
2013-06-28 |
Biotechnolog Forschung Gmbh |
Process for preparing epothilones with a modified side chain and compounds prepared by this process
|
US6605599B1
(en)
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
US6320045B1
(en)
|
1997-12-04 |
2001-11-20 |
Bristol-Myers Squibb Company |
Process for the reduction of oxiranyl epothilones to olefinic epothilones
|
US6365749B1
(en)
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
US6683100B2
(en)
|
1999-01-19 |
2004-01-27 |
Novartis Ag |
Organic compounds
|
US6380395B1
(en)
|
1998-04-21 |
2002-04-30 |
Bristol-Myers Squibb Company |
12, 13-cyclopropane epothilone derivatives
|
US6498257B1
(en)
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
DE19826988A1
(de)
*
|
1998-06-18 |
1999-12-23 |
Biotechnolog Forschung Gmbh |
Epothilon-Nebenkomponenten
|
DE69804448T2
(de)
*
|
1998-08-05 |
2002-11-07 |
Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) |
Epothilon A N-Oxid und/oder Epothilon B N-Oxid enthaltende pharmazeutische Agentien
|
US6780620B1
(en)
|
1998-12-23 |
2004-08-24 |
Bristol-Myers Squibb Company |
Microbial transformation method for the preparation of an epothilone
|
US6596875B2
(en)
|
2000-02-07 |
2003-07-22 |
James David White |
Method for synthesizing epothilones and epothilone analogs
|
DE19907588A1
(de)
*
|
1999-02-22 |
2000-08-24 |
Biotechnolog Forschung Gmbh |
C-21 Modifizierte Epothilone
|
ID29829A
(id)
|
1999-02-22 |
2001-10-11 |
Bristol Myers Squibb Co |
Epotilon termodifikasi pada c-21
|
US20020058286A1
(en)
*
|
1999-02-24 |
2002-05-16 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US6291684B1
(en)
|
1999-03-29 |
2001-09-18 |
Bristol-Myers Squibb Company |
Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
|
RU2312860C2
(ru)
|
1999-04-15 |
2007-12-20 |
Бристол-Маерс Сквибб Компани |
Циклические ингибиторы протеинтирозинкиназ
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
AU772750C
(en)
*
|
1999-04-30 |
2005-02-24 |
Schering Aktiengesellschaft |
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
|
AR023792A1
(es)
*
|
1999-04-30 |
2002-09-04 |
Bayer Schering Pharma Ag |
Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
|
WO2001024763A2
(fr)
|
1999-10-01 |
2001-04-12 |
Immunogen, Inc. |
Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
|
US6518421B1
(en)
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
US6593115B2
(en)
|
2000-03-24 |
2003-07-15 |
Bristol-Myers Squibb Co. |
Preparation of epothilone intermediates
|
US6589968B2
(en)
*
|
2001-02-13 |
2003-07-08 |
Kosan Biosciences, Inc. |
Epothilone compounds and methods for making and using the same
|
UA75365C2
(en)
|
2000-08-16 |
2006-04-17 |
Bristol Myers Squibb Co |
Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
|
WO2002058699A1
(fr)
*
|
2001-01-25 |
2002-08-01 |
Bristol-Myers Squibb Company |
Formes pharmaceutiques d'epothilones pour administration orale
|
RU2003126171A
(ru)
|
2001-01-25 |
2005-02-27 |
Бристол-Маерс Сквибб Компани (Us) |
Парентеральный состав, содержащий аналоги эпотилона
|
YU58203A
(sh)
|
2001-01-25 |
2006-08-17 |
Bristol-Myers Squibb Company |
Postupci primene epotilonskih analoga za lečenje kancera
|
US6893859B2
(en)
*
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
EP1368030A1
(fr)
|
2001-02-20 |
2003-12-10 |
Bristol-Myers Squibb Company |
Derives d'epothilone destines au traitement de tumeurs refractaires
|
EP1385529A4
(fr)
|
2001-02-20 |
2007-05-09 |
Bristol Myers Squibb Co |
Traitement de tumeurs refractaires a l'aide de derives d'epothilone
|
IL157312A0
(en)
*
|
2001-02-27 |
2004-02-19 |
Biotechnolog Forschung Gmbh |
Processes for the preparation of epothilone derivatives and compounds produced thereby
|
CZ305799B6
(cs)
|
2001-03-14 |
2016-03-23 |
Bristol-Myers Squibb Company |
Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
|
MXPA03010909A
(es)
|
2001-06-01 |
2004-02-17 |
Bristol Myers Squibb Co |
Derivados de epotilona.
|
TW200303202A
(en)
|
2002-02-15 |
2003-09-01 |
Bristol Myers Squibb Co |
Method of preparation of 21-amino epothilone derivatives
|
PL371098A1
(en)
*
|
2002-03-08 |
2005-06-13 |
Novartis Ag |
Combinations comprising epothilone derivatives and alkylating agents
|
US7211593B2
(en)
|
2002-03-12 |
2007-05-01 |
Bristol-Myers Squibb Co. |
C12-cyano epothilone derivatives
|
EP1483251B1
(fr)
|
2002-03-12 |
2009-12-23 |
Bristol-Myers Squibb Company |
Derives de c3-cyano epothilone
|
TW200403994A
(en)
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
TW200400191A
(en)
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7008936B2
(en)
|
2002-06-14 |
2006-03-07 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
US6921769B2
(en)
|
2002-08-23 |
2005-07-26 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
CN1759115A
(zh)
|
2002-08-23 |
2006-04-12 |
索隆-基特林癌症研究协会 |
埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
GB0221312D0
(en)
*
|
2002-09-13 |
2002-10-23 |
Novartis Ag |
Organic compounds
|
EP2287168B1
(fr)
|
2002-09-23 |
2013-02-13 |
Bristol-Myers Squibb Company |
Procédés de préparation, isolation et purification d'épothilone B, et structures de cristaux à rayons X d'épothilone B
|
EP1567487A4
(fr)
|
2002-11-15 |
2005-11-16 |
Bristol Myers Squibb Co |
Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
DK1817013T3
(da)
*
|
2004-11-18 |
2008-10-13 |
Brystol Myers Squibb Company |
Enterisk coatet kugle omfattende Ixabepilon
|
WO2006055742A1
(fr)
*
|
2004-11-18 |
2006-05-26 |
Bristol-Myers Squibb Company |
Bille enrobee de keratine comprenant de l'epothilone ou un analogue d'epothilone, ainsi que preparation et administration de cette bille
|
JP4954983B2
(ja)
|
2005-05-18 |
2012-06-20 |
ファーマサイエンス・インコーポレイテッド |
Birドメイン結合化合物
|
AU2007250443B2
(en)
|
2006-05-16 |
2013-06-13 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
EP2089411A4
(fr)
|
2006-12-04 |
2010-01-27 |
Univ Illinois |
Compositions et procédés pour le traitement du cancer avec des cuprédoxines et de l'adn riche en cpg
|
SG10201501095WA
(en)
|
2010-02-12 |
2015-04-29 |
Pharmascience Inc |
Iap bir domain binding compounds
|
EA035193B1
(ru)
|
2010-05-18 |
2020-05-14 |
Серулин Фарма Инк. |
Композиции и способы лечения аутоиммунных и других заболеваний
|
BR112013018534B1
(pt)
|
2011-01-20 |
2021-04-06 |
Board Of Regents, The University Of Texas System |
Agente de contraste, seus métodos de preparação, e produto de combinação
|
RU2617402C2
(ru)
|
2011-06-10 |
2017-04-25 |
Мерсана Терапьютикс, Инк. |
Конъюгаты белок-полимер-лекарственное средство
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
US9725477B2
(en)
|
2012-11-17 |
2017-08-08 |
Beijing Fswelcome Technology Development Co., Ltd |
Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
|
AU2013359506B2
(en)
|
2012-12-10 |
2018-05-24 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
EP2931316B1
(fr)
|
2012-12-12 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Conjugués hydroxy-polymère-médicament-protéine
|
EA201600003A1
(ru)
|
2013-06-11 |
2016-06-30 |
Байер Фарма Акциенгезельшафт |
КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
|
DK3054991T3
(da)
|
2013-10-11 |
2019-05-06 |
Mersana Therapeutics Inc |
Protein-polymer-lægemiddelkonjugater
|
IL245009B
(en)
|
2013-10-11 |
2022-08-01 |
Asana Biosciences Llc |
Protein-polymer-drug conjugates
|
EP3474901A1
(fr)
|
2016-06-27 |
2019-05-01 |
Tagworks Pharmaceuticals B.V. |
Tétrazine clivable utilisée dans l'activation de médicaments bio-orthogonaux
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
WO2018237262A1
(fr)
|
2017-06-22 |
2018-12-27 |
Mersana Therapeutics, Inc. |
Procédés de production de matrices polymères transportant des médicaments, et conjugués protéine-polymère-médicament
|
EP3788032B1
(fr)
|
2018-05-04 |
2024-01-24 |
Tagworks Pharmaceuticals B.V. |
Composés comprenant un lieur pour augmenter la stabilité de transcyclooctène
|
WO2019212356A1
(fr)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B .V. |
Tétrazines pour un rendement élevé de conjugaison de chimie click in vivo et un rendement élevé de libération de chimie click
|
EP3873534A1
(fr)
|
2018-10-29 |
2021-09-08 |
Mersana Therapeutics, Inc. |
Conjugués anticorps-médicament modifiés par une cystéine avec des lieurs contenant des peptides
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
AU2020297253B2
(en)
|
2019-06-17 |
2024-05-23 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
CA3230774A1
(fr)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Nouveaux variants d'aminoacyl-arnt synthetase pour l'expansion de code genetique dans des eucaryotes
|
CA3238627A1
(fr)
|
2021-11-25 |
2023-06-01 |
Christine Kohler |
Conjugues anticorps-charge utile ameliores (apc) prepares par conjugaison specifique a un site a l'aide d'une expansion de code genetique
|
EP4186529A1
(fr)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Conjugués anticorps-charge utile améliorés (apcs) préparés par conjugaison spécifique à un site à l'aide d'une expansion de code génétique
|
US20250135011A1
(en)
|
2021-12-08 |
2025-05-01 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
US20250114489A1
(en)
|
2022-02-15 |
2025-04-10 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
AU2023308528A1
(en)
|
2022-07-15 |
2025-01-23 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
AU2023358214A1
(en)
|
2022-10-12 |
2025-05-08 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
WO2024153789A1
(fr)
|
2023-01-20 |
2024-07-25 |
Basf Se |
Composition de biopolymère stabilisée, sa fabrication et son utilisation
|
WO2024191293A1
(fr)
|
2023-03-10 |
2024-09-19 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctène à lieur t amélioré
|
WO2025021929A1
(fr)
|
2023-07-27 |
2025-01-30 |
Veraxa Biotech Gmbh |
Composés de trans-cyclooctène hydrophiles (hytco), constructions et conjugués les contenant
|
WO2025056807A1
(fr)
|
2023-09-15 |
2025-03-20 |
Basf Se |
Compositions biopolymère stabilisées, leur fabrication et utilisation
|